Bharat Biotech is seeking international manufacturing partners as it targets a billion doses of its COVID-19 vaccine each year, the company said yesterday.
Covaxin, the company’s home-grown COVID-19 vaccine approved for emergency use in India, is one of two shots driving the country’s massive vaccination programme.
However, Bharat Biotech has struggled to boost output, missing supply commitments to the Indian government, which is also relying on a version of the AstraZeneca vaccine produced by the Serum Institute of India (SII) and Russia’s Sputnik V vaccine.
Bharat Biotech said it was exploring opportunities with its international partners who have expertise in commercial-scale manufacturing of inactivated viral vaccines.
“We want to ensure that Bharat Biotech can ably meet the demand for Covaxin such that individuals across the country, and the globe, have access to the vaccine,” Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech, said in a statement.